Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents.
COVID-19
cell-mediated immunity
elderly
long-term care facility
neutralizing antibodies
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
04
07
2022
received:
20
04
2022
accepted:
07
07
2022
entrez:
30
8
2022
pubmed:
31
8
2022
medline:
1
9
2022
Statut:
ppublish
Résumé
Long-term care facilities (LTCF) residents are at high risk for severe coronavirus disease 2019 (COVID-19), and therefore, COVID-19 vaccinations were prioritized for residents and personnel in Finland at the beginning of 2021. We investigated COVID-19 outbreaks in two LTCFs, where residents were once or twice vaccinated. After the outbreaks we measured immunoglobulin G (IgG) antibodies to severe acute respiratory syndrome coronavirus 2 spike glycoprotein, neutralizing antibody (NAb) titers, and cell-mediated immunity markers from residents and healthcare workers (HCWs). In LTFC-1, the outbreak was caused by an Alpha variant (B.1.1.7) and the attack rate (AR) among once vaccinated residents was 23%. In LTCF-2 the outbreak was caused by a Beta variant (B.1.351). Its AR was 47% although all residents had received their second dose 1 month before the outbreak. We observed that vaccination had induced lower IgG concentrations, NAb titers and cell-mediated immune responses in residents compared to HCWs. Only 1/8 residents had NAb to the Beta variant after two vaccine doses. The vaccinated elderly remain susceptible to breakthrough infections caused by Alpha and Beta variants. The weaker vaccine response in the elderly needs to be addressed in vaccination protocols, while new variants capable of evading vaccine-induced immunity continue to emerge.
Identifiants
pubmed: 36039644
doi: 10.1002/iid3.679
pmc: PMC9382858
doi:
Substances chimiques
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e679Informations de copyright
© 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Eur J Immunol. 2021 Dec;51(12):3202-3213
pubmed: 34580856
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
JAMA. 2022 Jan 11;327(2):179-181
pubmed: 34914825
Clin Infect Dis. 2022 Feb 11;74(3):517-520
pubmed: 33993228
Biomed Res Int. 2020 Nov 4;2020:8870249
pubmed: 33204723
Clin Infect Dis. 2022 Mar 1;74(4):751-752
pubmed: 34091665
Eur J Immunol. 2022 May;52(5):816-824
pubmed: 35312186
Tidsskr Nor Laegeforen. 2020 Jun 18;140(11):
pubmed: 32815356
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826
pubmed: 34915551
Front Immunol. 2022 Jan 25;13:816220
pubmed: 35145522
PLoS One. 2021 Nov 18;16(11):e0258704
pubmed: 34793476
Vaccines (Basel). 2021 Jul 01;9(7):
pubmed: 34358130
Lancet Infect Dis. 2021 Nov;21(11):1529-1538
pubmed: 34174193
Nat Commun. 2021 Apr 16;12(1):2283
pubmed: 33863907
JAMA Netw Open. 2021 Sep 1;4(9):e2125294
pubmed: 34515786
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Euro Surveill. 2020 Mar;25(11):
pubmed: 32209163
EClinicalMedicine. 2021 Dec;42:101190
pubmed: 34870134
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Microbiol Spectr. 2021 Dec 22;9(3):e0113121
pubmed: 34787485